AbstractBackgroundThe ability of preclinical neuroimaging in rodent models of Alzheimer’s Disease and Related Dementia (ADRD) to assess the progression of disease is increasingly providing novel insights into AD, like human AD imaging. Preclinical studies have the advantage of being able to directly correlate findings to the observed neuropathology. Recently, University of California Irvine and Indiana University School of Medicine along with Jackson Laboratories were awarded funding to design and phenotype relevant mouse models of late onset AD (LOAD), forming the MODEL AD consortium (https://www.model‐ad.org/). Imaging cores from these will utilize existing state of the art translationally relevant medical imaging methodologies as well as ascertain feasibility of emerging imaging methods for increased diagnostic sensitivity.MethodTwo primary imaging modalities will be utilized: high‐field MRI (9.4T and 17.6T) and PET/CT. Deep MRI phenotyping are based on the accepted human‐AD standards like ADNI (Structural T2W, FLAIR, diffusion, perfusion (PWI), susceptibility, and functional MRI and MR spectroscopy). Novel histological vessel painting combined with PWI will assess vascular modifications. PET imaging will evaluate brain metabolism (18F‐FDG), regional perfusion (64Cu‐PTSM), amyloid (18F‐AV45), tau (18F‐AV1451), neuroinflammation (18F‐CPPC and 18F‐GSK1482160), and astrogliosis (18F‐FEBU) markers in new mouse models.ResultMODEL AD consortia will utilize platform mice (Table 1) across their lifespans and effects after being fed a high fat diet. Known and emerging GWAS risk variants for AD will be added to these platform mice to better replicate human AD. Neuroimaging data will be presented from PET/CT and MRI, focusing on exemplars from relevant AD mouse models including platform mice. A long‐term goal of the MODEL‐AD Imaging cores is to co‐register MRI, PET/CT and vascular measures to concordant histopathological and spatial RNA data. The cores have developed state‐of‐the‐art analytical pipelines to process imaging data to support spatial and temporal localization of ADRD.ConclusionThe MODEL AD consortium (UCI/IUSM/Jax) will develop new and novel AD mouse models and the imaging cores will deeply phenotype these models using existing and emerging neuroimaging methods and analytic approaches, using MRI and PET/CT. All data will be made available to AD researchers via the Sage Knowledge Network (https://adknowledgeportal.synapse.org/).